Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients: A feasibility study

Jonathan A. Gutman, S. I. Bearman, Y. Nieto, J. W. Sweetenham, R. B. Jones, E. J. Shpall, C. Zeng, A. Baron, P. A. McSweeney

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

We report outcomes in advanced lymphoma patients (n = 32) who enrolled in a trial of prospectively planned combined autologous/ reduced-intensity transplantation (RIT) (n = 25) or who received RIT shortly after prior autografting because of high relapse risk or progressive disease (n = 7). Nine patients on the autologous/RIT transplant protocol did not proceed to planned RIT because of patient choice (n = 4), disease progression (n = 3), toxicity (n = 1), or no adequate donor (n = 1). Among the 23 other patients, RIT was started a median of 59 days (range 31-123) after autologous transplant. Fifteen patients had related donors, five patients had unrelated donors, and three patients had cord blood donors. Among all patients completing RIT, the median overall survival time was 385 days (95% CI 272-792), and the median relapse-free survival time was 157 days (95% CI 119-385). At the time of reporting, six patients (26%) remain alive and three patients (13%) remain alive without relapse. The 100-day transplant-related mortality (TRM) was 9% among all patients and was 0% among matched sibling donors. Overall TRM was 43%. Tandem transplant is feasible in advanced lymphoma with low early TRM. However, practical challenges associated with the strategy were significant and high levels of late TRM due to graft-versus-host disease and infections suggest that modifications of the procedure will be needed to improve outcomes and patient retention.

Original languageEnglish (US)
Pages (from-to)443-451
Number of pages9
JournalBone Marrow Transplantation
Volume36
Issue number5
DOIs
StatePublished - Sep 1 2005
Externally publishedYes

Fingerprint

Autologous Transplantation
Homologous Transplantation
Feasibility Studies
Immunotherapy
Lymphoma
Transplantation
Transplants
Mortality
Tissue Donors
Recurrence
Unrelated Donors
Survival
Autografts
Graft vs Host Disease
Blood Donors
Fetal Blood
Disease Progression
Siblings

Keywords

  • Lymphoma
  • Nonmyeloablative transplant
  • Reduced-intensity transplant
  • Tandem transplant

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients : A feasibility study. / Gutman, Jonathan A.; Bearman, S. I.; Nieto, Y.; Sweetenham, J. W.; Jones, R. B.; Shpall, E. J.; Zeng, C.; Baron, A.; McSweeney, P. A.

In: Bone Marrow Transplantation, Vol. 36, No. 5, 01.09.2005, p. 443-451.

Research output: Contribution to journalArticle

Gutman, Jonathan A. ; Bearman, S. I. ; Nieto, Y. ; Sweetenham, J. W. ; Jones, R. B. ; Shpall, E. J. ; Zeng, C. ; Baron, A. ; McSweeney, P. A. / Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients : A feasibility study. In: Bone Marrow Transplantation. 2005 ; Vol. 36, No. 5. pp. 443-451.
@article{5710830d5e1143a6aa1d898abbfa498c,
title = "Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients: A feasibility study",
abstract = "We report outcomes in advanced lymphoma patients (n = 32) who enrolled in a trial of prospectively planned combined autologous/ reduced-intensity transplantation (RIT) (n = 25) or who received RIT shortly after prior autografting because of high relapse risk or progressive disease (n = 7). Nine patients on the autologous/RIT transplant protocol did not proceed to planned RIT because of patient choice (n = 4), disease progression (n = 3), toxicity (n = 1), or no adequate donor (n = 1). Among the 23 other patients, RIT was started a median of 59 days (range 31-123) after autologous transplant. Fifteen patients had related donors, five patients had unrelated donors, and three patients had cord blood donors. Among all patients completing RIT, the median overall survival time was 385 days (95{\%} CI 272-792), and the median relapse-free survival time was 157 days (95{\%} CI 119-385). At the time of reporting, six patients (26{\%}) remain alive and three patients (13{\%}) remain alive without relapse. The 100-day transplant-related mortality (TRM) was 9{\%} among all patients and was 0{\%} among matched sibling donors. Overall TRM was 43{\%}. Tandem transplant is feasible in advanced lymphoma with low early TRM. However, practical challenges associated with the strategy were significant and high levels of late TRM due to graft-versus-host disease and infections suggest that modifications of the procedure will be needed to improve outcomes and patient retention.",
keywords = "Lymphoma, Nonmyeloablative transplant, Reduced-intensity transplant, Tandem transplant",
author = "Gutman, {Jonathan A.} and Bearman, {S. I.} and Y. Nieto and Sweetenham, {J. W.} and Jones, {R. B.} and Shpall, {E. J.} and C. Zeng and A. Baron and McSweeney, {P. A.}",
year = "2005",
month = "9",
day = "1",
doi = "10.1038/sj.bmt.1705081",
language = "English (US)",
volume = "36",
pages = "443--451",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients

T2 - A feasibility study

AU - Gutman, Jonathan A.

AU - Bearman, S. I.

AU - Nieto, Y.

AU - Sweetenham, J. W.

AU - Jones, R. B.

AU - Shpall, E. J.

AU - Zeng, C.

AU - Baron, A.

AU - McSweeney, P. A.

PY - 2005/9/1

Y1 - 2005/9/1

N2 - We report outcomes in advanced lymphoma patients (n = 32) who enrolled in a trial of prospectively planned combined autologous/ reduced-intensity transplantation (RIT) (n = 25) or who received RIT shortly after prior autografting because of high relapse risk or progressive disease (n = 7). Nine patients on the autologous/RIT transplant protocol did not proceed to planned RIT because of patient choice (n = 4), disease progression (n = 3), toxicity (n = 1), or no adequate donor (n = 1). Among the 23 other patients, RIT was started a median of 59 days (range 31-123) after autologous transplant. Fifteen patients had related donors, five patients had unrelated donors, and three patients had cord blood donors. Among all patients completing RIT, the median overall survival time was 385 days (95% CI 272-792), and the median relapse-free survival time was 157 days (95% CI 119-385). At the time of reporting, six patients (26%) remain alive and three patients (13%) remain alive without relapse. The 100-day transplant-related mortality (TRM) was 9% among all patients and was 0% among matched sibling donors. Overall TRM was 43%. Tandem transplant is feasible in advanced lymphoma with low early TRM. However, practical challenges associated with the strategy were significant and high levels of late TRM due to graft-versus-host disease and infections suggest that modifications of the procedure will be needed to improve outcomes and patient retention.

AB - We report outcomes in advanced lymphoma patients (n = 32) who enrolled in a trial of prospectively planned combined autologous/ reduced-intensity transplantation (RIT) (n = 25) or who received RIT shortly after prior autografting because of high relapse risk or progressive disease (n = 7). Nine patients on the autologous/RIT transplant protocol did not proceed to planned RIT because of patient choice (n = 4), disease progression (n = 3), toxicity (n = 1), or no adequate donor (n = 1). Among the 23 other patients, RIT was started a median of 59 days (range 31-123) after autologous transplant. Fifteen patients had related donors, five patients had unrelated donors, and three patients had cord blood donors. Among all patients completing RIT, the median overall survival time was 385 days (95% CI 272-792), and the median relapse-free survival time was 157 days (95% CI 119-385). At the time of reporting, six patients (26%) remain alive and three patients (13%) remain alive without relapse. The 100-day transplant-related mortality (TRM) was 9% among all patients and was 0% among matched sibling donors. Overall TRM was 43%. Tandem transplant is feasible in advanced lymphoma with low early TRM. However, practical challenges associated with the strategy were significant and high levels of late TRM due to graft-versus-host disease and infections suggest that modifications of the procedure will be needed to improve outcomes and patient retention.

KW - Lymphoma

KW - Nonmyeloablative transplant

KW - Reduced-intensity transplant

KW - Tandem transplant

UR - http://www.scopus.com/inward/record.url?scp=30944456926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30944456926&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1705081

DO - 10.1038/sj.bmt.1705081

M3 - Article

C2 - 15995712

AN - SCOPUS:30944456926

VL - 36

SP - 443

EP - 451

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 5

ER -